Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945846079> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2945846079 endingPage "2473" @default.
- W2945846079 startingPage "2467" @default.
- W2945846079 abstract "Background/Aim: National guidelines offer little guidance on the use of PSA progression (PSA increase as defined below) as a clinical endpoint in metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to examine treatment patterns/outcomes with abiraterone (abi)/enzalutamide (enza) throughout PSA progression and near the end of life (EOL). Patients and Methods: Cases of mCRPC treated with abi or enza from the New York Veterans Affairs (VA) from 6/2011-8/2017 were reviewed. Regression analyses were conducted to identify factors associated with continuation of abi/enza treatment up to the EOL, and survival. Results: Of 184 patients, 72 received abi alone, 28 received enza alone, and 84 received both. Treatment was changed for PSA progression alone in 39.1% (abi) and 25.7% (enza) of patients. A total of 37 patients (20%) received abi/enza within 1 month before death, 30% of whom were receiving hospice services. Older patients and black patients were less likely to receive abi/enza up to the EOL. Conclusion: Abi/enza are frequently discontinued for PSA progression alone and continued at EOL. The clinical benefit of these practices warrants additional study." @default.
- W2945846079 created "2019-05-29" @default.
- W2945846079 creator A5004245154 @default.
- W2945846079 creator A5031483568 @default.
- W2945846079 creator A5032146906 @default.
- W2945846079 creator A5034221381 @default.
- W2945846079 creator A5037951527 @default.
- W2945846079 creator A5044063936 @default.
- W2945846079 creator A5060646060 @default.
- W2945846079 creator A5066766559 @default.
- W2945846079 date "2019-05-01" @default.
- W2945846079 modified "2023-09-27" @default.
- W2945846079 title "Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression" @default.
- W2945846079 doi "https://doi.org/10.21873/anticanres.13366" @default.
- W2945846079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31092441" @default.
- W2945846079 hasPublicationYear "2019" @default.
- W2945846079 type Work @default.
- W2945846079 sameAs 2945846079 @default.
- W2945846079 citedByCount "9" @default.
- W2945846079 countsByYear W29458460792019 @default.
- W2945846079 countsByYear W29458460792020 @default.
- W2945846079 countsByYear W29458460792021 @default.
- W2945846079 countsByYear W29458460792022 @default.
- W2945846079 countsByYear W29458460792023 @default.
- W2945846079 crossrefType "journal-article" @default.
- W2945846079 hasAuthorship W2945846079A5004245154 @default.
- W2945846079 hasAuthorship W2945846079A5031483568 @default.
- W2945846079 hasAuthorship W2945846079A5032146906 @default.
- W2945846079 hasAuthorship W2945846079A5034221381 @default.
- W2945846079 hasAuthorship W2945846079A5037951527 @default.
- W2945846079 hasAuthorship W2945846079A5044063936 @default.
- W2945846079 hasAuthorship W2945846079A5060646060 @default.
- W2945846079 hasAuthorship W2945846079A5066766559 @default.
- W2945846079 hasBestOaLocation W29458460791 @default.
- W2945846079 hasConcept C121608353 @default.
- W2945846079 hasConcept C126322002 @default.
- W2945846079 hasConcept C143998085 @default.
- W2945846079 hasConcept C203092338 @default.
- W2945846079 hasConcept C2776421732 @default.
- W2945846079 hasConcept C2776551883 @default.
- W2945846079 hasConcept C2780192828 @default.
- W2945846079 hasConcept C29456083 @default.
- W2945846079 hasConcept C535046627 @default.
- W2945846079 hasConcept C61367390 @default.
- W2945846079 hasConcept C71924100 @default.
- W2945846079 hasConceptScore W2945846079C121608353 @default.
- W2945846079 hasConceptScore W2945846079C126322002 @default.
- W2945846079 hasConceptScore W2945846079C143998085 @default.
- W2945846079 hasConceptScore W2945846079C203092338 @default.
- W2945846079 hasConceptScore W2945846079C2776421732 @default.
- W2945846079 hasConceptScore W2945846079C2776551883 @default.
- W2945846079 hasConceptScore W2945846079C2780192828 @default.
- W2945846079 hasConceptScore W2945846079C29456083 @default.
- W2945846079 hasConceptScore W2945846079C535046627 @default.
- W2945846079 hasConceptScore W2945846079C61367390 @default.
- W2945846079 hasConceptScore W2945846079C71924100 @default.
- W2945846079 hasIssue "5" @default.
- W2945846079 hasLocation W29458460791 @default.
- W2945846079 hasOpenAccess W2945846079 @default.
- W2945846079 hasPrimaryLocation W29458460791 @default.
- W2945846079 hasRelatedWork W122177069 @default.
- W2945846079 hasRelatedWork W2414042649 @default.
- W2945846079 hasRelatedWork W2584454163 @default.
- W2945846079 hasRelatedWork W2765333766 @default.
- W2945846079 hasRelatedWork W2783882412 @default.
- W2945846079 hasRelatedWork W2917061290 @default.
- W2945846079 hasRelatedWork W2942985299 @default.
- W2945846079 hasRelatedWork W2982156914 @default.
- W2945846079 hasRelatedWork W2996229517 @default.
- W2945846079 hasRelatedWork W4200047397 @default.
- W2945846079 hasVolume "39" @default.
- W2945846079 isParatext "false" @default.
- W2945846079 isRetracted "false" @default.
- W2945846079 magId "2945846079" @default.
- W2945846079 workType "article" @default.